The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Olanzapine‐Associated Diabetes Mellitus
Abstract
Study Objective. To explore the clinical characteristics of hyperglycemia in patients treated with olanzapine. Design. Retrospective, epidemiologic survey of spontaneously reported adverse events related to olanzapine therapy. Setting. Government‐affiliated drug evaluation center. Patients. Two hundred thirty‐seven patients with olanzapine‐associated diabetes or hyperglycemia. Intervention. One hundred ninety‐six cases from January 1994‐May 15, 2001, were identified with the United States Food and Drug Administration's MedWatch Drug Surveillance System, and 41 cases published through May 15, 2001, were identified with MEDLINE or through meeting abstracts. Measurements and Main Results. Of the 237 cases, 188 were new‐onset diabetes, 44 were exacerbations of preexistent disease, and 5 could not be classified. Mean patient age for newly diagnosed cases was 40.7 ± 12.9 years and male:female ratio was 1.8. Seventy‐three percent of all cases of hyperglycemia appeared within 6 months of start of olanzapine therapy. Eighty patients had metabolic acidosis or ketosis, 41 had glucose levels of 1000 mg/dl or greater, and 15 patients died. When olanzapine was discontinued or the dosage decreased, 78% of patients had improved glycemic control. Hyperglycemia recurred in 8 of 10 cases with rechallenge. Conclusions. Number of reports, temporal relationship to start of olanzapine therapy, relatively young age, and improvement on drug withdrawal suggest that olanzapine may precipitate or unmask diabetes in susceptible patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
(2012) · SpringerReference · doi:10.1007/springerreference_121117 · Cited by 20,570
Incidence of Adverse Drug Events and Potential Adverse Drug Events: Implications for Prevention
Bates, D. W. (1995) · JAMA · doi:10.1001/jama.1995.03530010043033 · Cited by 2,127
Clozapine, Diabetes Mellitus, Weight Gain, and Lipid Abnormalities: A Five-Year Naturalistic Study
Henderson, D. C., Cagliero, E., Gray, C., Nasrallah, R. A., Hayden, D. L., Schoenfeld, D. A., & Goff, D. C. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.6.975 · Cited by 701
Inman, W. H., & Vessey, M. P. (1968) · BMJ · doi:10.1136/bmj.2.5599.193 · Cited by 452
Kaplan and Sadock's synopsis of psychiatry
Sadock, B. J., & Sadock, V. A. (1998) · Cited by 450
Novel antipsychotics and new onset diabetes
Wirshing, D. A., Spellberg, B. J., Erhart, S. M., Marder, S. R., & Wirshing, W. C. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00100-0 · Cited by 407
ARIEFF, A. I., & CARROLL, H. J. (1972) · Medicine · doi:10.1097/00005792-197203000-00001 · Cited by 271
Attitudinal survey of voluntary reporting of adverse drug reactions
Eland, Belton, Grootheest, V., Meiners, Rawlins, & Stricker (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00060.x · Cited by 256
Koller, E., Schneider, B., Bennett, K., & Dubitsky, G. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)01000-2 · Cited by 250
Self-citationNew-Onset Diabetes Mellitus and Diabetic Ketoacidosis Associated With Olanzapine Treatment
Goldstein, L. E., Sporn, J., Brown, S., Kim, H., Finkelstein, J., Gaffey, G. K., Sachs, G., & Stern, T. A. (1999) · Psychosomatics · doi:10.1016/s0033-3182(99)71210-7 · Cited by 220
Cited by
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
Consensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554
Second-Generation (Atypical) Antipsychotics and Metabolic Effects: A Comprehensive Literature Review
Newcomer, J. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519001-00001 · Cited by 1,340
Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles
Nasrallah, H. A. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002066 · Cited by 714
Wysowski, D. K., & Swartz, L. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1363 · Cited by 471
Adverse Effects of Atypical Antipsychotics: Differential Risk and Clinical Implications
Haddad, P. M., & Sharma, S. G. (2007) · CNS Drugs · doi:10.2165/00023210-200721110-00004 · Cited by 456
Gelenberg, A. J. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0101 · Cited by 356
Henderson, D. C., Cagliero, E., Copeland, P. M., Borba, C. P., Evins, A. E., Hayden, D., Weber, M. T., Anderson, E. J., Allison, D. B., Daley, T. B., et al. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.1.19 · Cited by 319
The metabolic effects of antipsychotic medications
Newcomer, J. W., & Haupt, D. W. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100803 · Cited by 315
“However, while drug-induced increases in adiposity may be the most common mechanism contributing to drug-induced changes in glucose metabolism, a significant minority of patients may experience glucose dysregulation independent of weight or adiposity differences (15,53,60,61,112,113).”
InfluentialThe Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children
Libowitz, M. R., & Nurmi, E. L. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.623681 · Cited by 99
Antipsychotics and diabetes: review of non-prospective data
Haddad, P. M. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.184.47.s80 · Cited by 71
“Koller and colleagues have published several analyses of anecdotal reports of diabetes occurring with clozapine (Koller et al, 2001), olanzapine (Koller & Doraiswamy, 2002), risperidone (Koller et al, 2003) and quetiapine (E. Koller, personal communication, 2003).”
BackgroundInfluentialRisk of Treatment-Emergent Diabetes Mellitus in Patients Receiving Antipsychotics
Citrome, L. L., Holt, R. I., Zachry, W. M., Clewell, J. D., Orth, P. A., Karagianis, J. L., & Hoffmann, V. P. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k141 · Cited by 64
Potential effectiveness and safety of olanzapine in refractory panic disorder
Hollifield, M., Thompson, P. M., Ruiz, J. E., & Uhlenhuth, E. H. (2005) · Depression and Anxiety · doi:10.1002/da.20050 · Cited by 58
Chue, P., & Kovacs, C. S. (2003) · Bipolar Disorders · doi:10.1111/j.1399-2406.2003.00063.x · Cited by 32
Drug-induced endocrine disorders in the intensive care unit
Thomas, Z., Bandali, F., McCowen, K., & Malhotra, A. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181dda0f2 · Cited by 30
Sumiyoshi, T., Roy, A., Anil, A. E., Jayathilake, K., Ertugrul, A., & Meltzer, H. Y. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000126668.67820.00 · Cited by 28
Brain stem as a target site for the metabolic side effects of olanzapine
Anwar, I. J., Miyata, K., & Zsombok, A. (2016) · Journal of Neurophysiology · doi:10.1152/jn.00387.2015 · Cited by 13
Metadata
- Authors
- Koller, E. A., & Doraiswamy, P. M.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2002-07
- Volume
- 22
- Issue
- 7
- Pages
- 841-852
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2131656182
- Cited by
- 303
- References
- 42
- FWCI
- 24.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.